Media stories about Echo Therapeutics (NASDAQ:ECTE) have been trending positive on Wednesday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Echo Therapeutics earned a coverage optimism score of 0.30 on Accern’s scale. Accern also assigned news headlines about the medical device company an impact score of 42.8269573770584 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Echo Therapeutics (NASDAQ:ECTE) remained flat at $0.04 during trading on Wednesday. The company had a trading volume of 6,030 shares. The company has a 50 day moving average of $0.05 and a 200 day moving average of $0.08. Echo Therapeutics has a 52 week low of $0.04 and a 52 week high of $0.93.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/positive-press-coverage-somewhat-unlikely-to-impact-echo-therapeutics-ecte-share-price/1496067.html.

About Echo Therapeutics

Echo Therapeutics, Inc is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment.

Receive News & Ratings for Echo Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Echo Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.